Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Profit After Tax (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Profit After Tax for 16 consecutive years, with -$37.5 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 6.67% to -$37.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$103.1 million through Dec 2025, down 30.07% year-over-year, with the annual reading at -$103.1 million for FY2025, 30.07% down from the prior year.
  • Profit After Tax hit -$37.5 million in Q4 2025 for Perspective Therapeutics, down from -$26.0 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$371000.0 in Q1 2023 to a low of -$40.2 million in Q4 2024.
  • Historically, Profit After Tax has averaged -$12.5 million across 5 years, with a median of -$10.7 million in 2023.
  • Biggest five-year swings in Profit After Tax: soared 72.46% in 2023 and later tumbled 3211.05% in 2024.
  • Year by year, Profit After Tax stood at -$1.6 million in 2021, then tumbled by 357.29% to -$7.3 million in 2022, then tumbled by 236.4% to -$24.7 million in 2023, then crashed by 62.79% to -$40.2 million in 2024, then grew by 6.67% to -$37.5 million in 2025.
  • Business Quant data shows Profit After Tax for CATX at -$37.5 million in Q4 2025, -$26.0 million in Q3 2025, and -$21.5 million in Q2 2025.